שווי כולל של החברה: XTL Bio (XTLB)

XTL Biopharmaceuticals focuses on developing treatments for blood cancer. The market price visualization on GURU.Markets, where the indicator stands at 5.19, illustrates the potential of the hMTS drug within the rare oncological pathology niche. The business relies on acquiring rights to new medications and forming alliances to combat lupus. High unmet demand for systemic autoimmune disorder therapies guarantees stable sales following successful tests.

XTL Biopharmaceuticals focuses on developing innovative antibodies for the treatment of systemic lupus erythematosus. The enterprise value (EV) reflects the total cost of acquiring the business, summing market capitalization and net debt. This metric allows for an assessment of the company's actual scale beyond the share price. Investors utilize it to analyze the efficiency of capital expenditures on research and development. The EV history clearly demonstrates the trend of the market valuation regarding the potential for future drug commercialization.